Dr. Reddy’s Laboratories Ltd. received approval for Elyxyb (celecoxib oral solution 25 mg/mL) from the U.S. Food and Drug Administration for the acute treatment of migraine with or without aura in adults.

Biogen filed a lawsuit against a New York life sciences company over alleged patent infringements related to the experimental Alzheimer’s disease treatment aducanumab.

The U.S. Food and Drug Administration has a busy week of possible drug approvals on the regulatory agency’s calendar, including Celgene’s ozanimod for relapsing forms of multiple sclerosis.

Dr. Ann McKee of Boston University studies the brains of deceased football players at the world’s largest brain bank, hoping to learn about the long-term impact of repeated head traumas for people ranging from professional athletes to victims of domestic abuse.

Eli Lilly priced the company’s acute migraine treatment Reyvow at $640 for a pack of eight pills.

Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.

Takeda Pharmaceutical has been on a tear over the past few weeks, striking deals to develop new therapies for various diseases. Now the Japan-based pharma powerhouse has announced a multi-year drug discovery deal with Charles River Laboratories.

Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.

Biohaven Pharmaceutical Holding Company Ltd. said two doses of an experimental treatment for acute migraine were effective in reducing headaches in a large study, sending the company’s shares up 8 percent.